We are live on ! Find out more
LIXTW

Lixte Biotechnology Warrants

Delisted

LIXTW was delisted on the 26th of November, 2025.

0 hedge funds and large institutions have $0 invested in Lixte Biotechnology Warrants in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.67% less ownership

Funds ownership: 1.67%0% (-1.7%)

100% less funds holding

Funds holding: 30 (-3)

100% less capital invested

Capital invested by funds: $3.6K → $0 (-$3.6K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
Holders Change
-3
Holders Change %
-100%
% of All Funds
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
3
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter
Name Holding Trade Value Shares
Change
Change in
Stake
CS
1
Clear Street
New York
-$3.12K -21,618 Closed
NFSG
2
Newbridge Financial Services Group
Florida
-$361 -2,500 Closed
UBS Group
3
UBS Group
Switzerland
-$125 -867 Closed

LIXTW Hedge Fund Activity: Q4 2025 in Review

0 of the 8,229 institutional investors tracked by Wall St. Rank reported a position in Lixte Biotechnology Warrants (LIXTW) for Q4 2025, worth a combined $0 — down 100% from $3.6K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of LIXTW and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Clear Street, exiting entirely with an estimated $3.12K sold.

  • 0 institutional investors held Lixte Biotechnology Warrants (LIXTW) as of Q4 2025, down from 3 in Q3 2025.
  • Funds reported $0 of Lixte Biotechnology Warrants stock for Q4 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Lixte Biotechnology Warrants positions in Q4 2025 and 3 closed out, a net change of -3 holders.
  • The largest Lixte Biotechnology Warrants seller in Q4 2025 was Clear Street, an estimated $3.12K sold.

Based on aggregated 13F filings for Q4 2025.